关于诺和龙®的声明

诺和诺德(中国)制药有限公司(“公司”)一直致力于为患者提供高质量的药品和注射装置并确保患者的用药安全。最近,个别地方的患者向公司反映其在当地药店购买的诺和龙®产品与以往服用的诺和龙®产品外观上有所不同。经公司调查,已经确认前述产品并非公司生产的诺和龙®产品而是假冒的诺和龙®产品,即假药。公司已向当地食品药品监督管理局报告了前述情况,当地食品药品监督管理局已经开始相关调查。

如果您怀疑您所购买的诺和龙®产品的真伪,公司在此提供了相关信息以协助您对所购产品进行比较鉴别。如果经过比较,您怀疑所购产品为假药,我们建议您立即与当地食品药品监督管理局和公司联系。

这是诺和龙®在中国上市10年以来,第一次发现假冒产品。为了保障患者的健康,公司会积极协助当地食品药品监督管理局对假药进行严厉打击。



 
Statement about NovoNorm ®

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (the “Company”) is committed to providing high quality drugs and devices to patients and to safeguarding high standards of patient safety. Recently the company was contacted by a handful of patients stating that the NovoNorm® tablets they had bought from local pharmacies appeared different to their usual NovoNorm®tablets. Following an investigation, Novo Nordisk has identified that these few tablets are not drugs produced by the company but are counterfeit tablets. Novo Nordisk has reported these incidents of counterfeit NovoNorm® tablets incidences to the Chinese regulatory authorities local FDA, and an investigation has subsequently been carried out by the relevant related local authorities.

Should patients be concerned their NovoNorm®tablets are counterfeit, the company has provided the following information in order to assist in distinguishing genuine NovoNorm®products from counterfeits. Should any products be suspected of being counterfeit after comparison with the information below, we highly recommend you immediately contact your local regulatory authorities and to the company.

This is the first time that Novo Nordisk has encountered counterfeit NovoNorm® tablets since it was launched in China more than 10 years ago. The Company is highly committed to working with local regulatory authorities to fight counterfeit products, in order to safeguard the health of patients.

媒体联络

 

刘颀  企业交流副总监

人力资源与企业交流部

联系电话:

(86) 10-59615614

 

常乐  公共关系项目经理

人力资源与企业交流部

联系电话:

(86) 10-59615780